ASX-listed Microba expands offering and UK footprint with IFL

29.2.2024

Over the last 10 years, our understanding of the importance of the gut to overall health has jumped forward in leaps and bounds. It is now well understood that microorganisms, including bacteria, archaea, fungi, and viruses living inside the human digestive tract (known collectively as the gut microbiome) are critical to many bodily functions. Not just important in digestion and nutrient absorption, the gut microbiome has far-reaching effects on immune function, mental health, inflammatory and autoimmune disease, skin health, heart health, and overall well-being.  

ASX-listed, Brisbane-based Microba has successfully commercialised a world-leading platform to test and analyse the human gut microbiome. Leveraging their diagnostics data, Microba then develops targeted therapeutics for microbiome-linked issues such as inflammatory bowel disease.  

To support it’s next phase of international growth, and based on some opportunities that had presented to the company, Microba enlisted InterFinancial to run a buyside process. This resulted in the 100% acquisition of UK-based Invivo Clinical. InterFinancial’s Health Sector lead, Michael Kakanis led the process. A Doctor of Immunology, Michael transitioned into Finance in 2017 and, having led several of InterFinancial’s deals in the health sector, was perfectly positioned to partner with Microba. 

Meeting challenging objectives head on

Through a thorough process of global opportunity assessment and due diligence, Invivo, a pioneer in UK microbiome testing, was confirmed as a strong candidate to support the next phase of Microba’s international growth. IFL helped build and strengthen the relationship between the parties and structure a deal that worked for the buyer, seller, and the public markets.  

Michael Kakanis says, “there were a few characteristics that increased the complexity of the deal. For starters,  Microba was acquiring in the UK – a very different time zone – so a lot of the deal was done between 5 pm and midnight. Microba also raised capital and issued equity, and had various stakeholders on both sides of the deal to manage actively. This included their strategic partner and shareholder, Sonic Healthcare, as well as the internal and external teams driving the due diligence process.” 

Crafting a deal in a tricky market

InterFinancial worked together with the team at Microba to ensure these requirements were achieved and no stone was left unturned. And, in December 2023, Microba completed the transaction, acquiring 100% of Invivo. The acquisition put Microba in a leading position in the local market, with deep access to the UK healthcare market spanning both the integrative healthcare market through Invivo, and the GP, specialist and dietician market through their Sonic partnership.  

“InterFinancial was instrumental in validating the Invivo opportunity, crafting a deal in a tricky market, and driving the deal through due diligence, signing and completion. InterFinancial ensured that not only the deal met our commercial criteria, but also aligned to our strategy and culture. They went over and above to get a deal done across multiple challenges through the process. A world-class team of professionals,” Dr Luke Reid, CEO, Microba.

29.9.2024

Sector dashboards September 2024

Our monthly sector dashboards are out! Our dashboards look at the valuation multiples across seven key sectors, each made up of a number of subsectors. The data takes into account the sale prices of similar companies based on; products, end markets, services, assets classes or other characteristics. The publications include all companies listed on the […]

Read more
29.9.2024

Investing in Consumer Goods and Retail: is it time to go shopping?

It’s been a challenging few years for Consumer Goods and Retail companies. The pandemic, supply chain disruptions, rising interest rates and cost of living pressures have all had an impact on profits in the sector.   Of course, some companies did quite well during the pandemic. Think online shopping, home delivery meal boxes and camping […]

Read more
17.9.2024

From lab coat to deal sheet: celebrating Michael Kakanis’ journey to Director

We’re thrilled to announce the promotion of Michael Kakanis to Director at InterFinancial and his recent appointment as Co-Chair of Healthcare at Clairfield International.   Michael’s journey is nothing short of inspiring. Working as a lecturer in Physiology and Biochemistry while completing his PhD in Immunology, Michael was all set for a long career in Academia. […]

Read more
03.9.2024

7 key challenges to overcome when investing in Australian renewable energy

Properly understanding the potential financial returns of an investment in the context of operations in the Australian Energy market  Renewable energy generation projects utilising solar, wind and battery technology find revenue sources from offtake agreements, arbitrage of wholesale electricity prices, providing grid stabilization services via mechanisms such as FCAS and by accessing green trading certificates […]

Read more
27.8.2024

Employee Q&A: Nasia Christodoulou

At InterFinancial, our strength lies in the passion and expertise of our talented team. Today, we’re shining the spotlight on Nasia Christodoulou, who joined us as a Research Assistant in January 2023 and has since progressed to Analyst. In this Q&A, Nasia gives us a glimpse into her daily routine, the challenges she overcomes, and […]

Read more
27.8.2024

Beyond the headline price: evaluating offers in M&A

When it comes to selling your business, it’s easy to get excited about the headline price offered by potential buyers. But before you pop the champagne, you will need to look beyond that big number and consider the finer details that can significantly impact how much money ends up in your pocket.  In this blog […]

Read more
27.8.2024

Sector dashboards August 2024

Our monthly sector dashboards are out! Our dashboards look at the valuation multiples across seven key sectors, each made up of a number of subsectors. The data takes into account the sale prices of similar companies based on; products, end markets, services, assets classes or other characteristics. The publications include all companies listed on the […]

Read more
27.8.2024

Everyone’s going private: current status of the P2P landscape

A few years ago, we ran some analysis on Public to Private (P2P) transactions to see what we could distil from the data. You can read the article here.   P2P or Take-Private simply means the takeover of a listed (public) company so that it then becomes a private company, either independently (typically with the […]

Read more
12.8.2024

EOFY2024: a year in review

Another year has flown by, and what a year it was! From strategic partnerships to international expansions, 2024 saw InterFinancial at the heart of some truly transformative partnerships. 13 transactions. Numerous opportunities created. As we look back on FY24, we’re excited to share the stories behind the numbers – stories of businesses taking bold steps, […]

Read more